The IBFM ALL Committee is a network that shares published and unpublished basic science and clinical trials data from AIEOP/BFM, ALLTogether, ALL-IC, Australian, and Japanese collaborators to promote the development of more effective and less toxic treatment strategies for childhood acute lymphoblastic leukemia (ALL). The committee and its members collaborate closely with US groups (The Children’s Oncology Group, St Jude Children’s Research Hospital, and the Dana Farber Consortium), including within the so-called Ponte di Legno consortium (PdL)) that share data on rare ALL subsets for the development of future clinical trials.

Committee members participate in organizing interim ALL meetings in Milan (January, annually), SIOPE meetings (annually), PdL meetings (at 1-2 years intervals), and in-between online meetings.

The committee chair is member of the IBFM Board, and the committee works closely with the other IBFM committees to promote research, meetings, and educational activities.

Scientific aims

To promote the development of more effective and less toxic treatment strategies for ALL.

Open and completed clinical trials

Open:

AIEOP-BFM ALL 2017 (2017 – ): Randomized clinical trial for ALL (age 1-18y)

EsPhALL2017-COGAALL1631: Randomized trial for patients with Ph+ ALLAIEOP-BFM ALL 2017 (2017-2023): Randomized clinical trial (age 1.0-21.9y)

ALLTogether-1 (2021 – ): Randomized clinical trial for ALL (age up to 45 years)

ALL-IC 2022 (3/2023 – ): Randomized clinical trial for ALL in countries with limited resources

Interfant-21 (2/2023 – ): Non-randomized clinical trial for all pts under 1y of age with KMT2A rear. ALL

Completed:

IDH (1991-1995): SR ALL

hSCT in VHR ALL (1995-2000)
VCR/Steroid Pulses (1995-2000): MR ALL
Interfant-99 (1999-2006): ALL below the age of one year (ALL<1y)
ALLIC-BFM 2002 (2002-2009): Randomized clinical protocol for ALL in countries with limited resources
ALL-SCT BFM 2003: HSCT in VHR ALL

EsPhALL (2004-2009): ALL positive for the t(9;22)[BCR/ABL] translocation

INTERFANT-06: Randomized clinical trial for ALL under 1y

AIEOP-BFM ALL 2000 (2000-2006): Randomized clinical trial for ALL (age 1-18y)
AIEOP-BFM ALL 2009: Randomized clinical trial for ALL (age 1-18y)

ALL IC-BFM 2009 (2010-2018): Randomized clinical trial for ALL in countries with limited resources

Selected publications

Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ; European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Münster Study Group (I-BFM-SG). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010. PMID: 20033054.

Schrappe M, Nachman J, Hunger S, Schmiegelow K, Conter V, Masera G, Pieters R, Pui CH. ‘Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)’. Leukemia. 2010. PMID: 20145664.

Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012. PMID: 22494120.

Jan Stary, Martin Zimmermann, Myriam Campbell, Luis Castillo, Eduardo Dibar, Svetlana Donska, Alejandro Gonzalez, Shai Izraeli, Dragana Janic, Janez Jazbec, Josip Konja, Emilia Kaiserova, Jerzy Kowalczyk, Gabor Kovacs, Chi-Kong Li, Edina Magyarosy, Alexander Popa, Batia Stark, Yahia Jabali, Jan Trka, Ondrej Hrusak, Hansjorg Riehm, Guiseppe Masera and Martin Schrappe. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized Intercontinental trial ALL IC BFM 2002. J Clin Oncol. 2013. PMID: 24344215. 

Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, Escherich G, Horibe K, Benoit YC, Izraeli S, Yeoh AE, Liang DC, Downing JR, Evans WE, Relling MV, Mullighan CG. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015. PMID: 26304874.

Schmiegelow K, Attarbaschi A, Barzilai S et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016. PMID: 27299279.

Hrusak O, de Haas V, Stancikova J, Vakrmanova B, Janotova I, Mejstrikova E, Capek V, Trka J, Zaliova M, Luks A, Bleckmann K, Möricke A, Irving J, Konatkowska B, Alexander TB, Inaba H, Schmiegelow K, Stokley S, Zemanova Z, Moorman AV, Rossi JG, Felice MS, Dalla-Pozza L, Morales J, Dworzak M, Buldini B, Basso G, Campbell M, Cabrera ME, Marinov N, Elitzur S, Izraeli S, Luria D, Feuerstein T, Kolenova A, Svec P, Kreminska O, Rabin KR, Polychronopoulou S, da Costa E, Marquart HV, Kattamis A, Ratei R, Reinhardt D, Choi JK, Schrappe M, Stary J. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood. 2018. PMID: 29720486.

Kearns PR, Vassal G, Ladenstein R, Schrappe M, Biondi A, Blanc P, Eggert A, Kienesberger A, Kozhaeva O, Pieters R, Schmiegelow K. A European paediatric cancer mission: aspiration or reality? Lancet Oncol. 2019. PMID: 31486360.

Den Boer ML, Cario G, Moorman AV, et al. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol. 2021. PMID: 33357483.

Peters C, Dalle JH, Locatelli F et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021. PMID: 33332189.

Andrés-Jensen L, Attarbaschi A, Bardi E et al. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. Lancet Haematol. 2021. PMID: 34171282.

Hirabayashi S, Butler ER, Ohki K, Kiyokawa N, Bergmann AK, Möricke A, Boer JM, Cavé H, Cazzaniga G, Yeoh AEJ, Sanada M, Imamura T, Inaba H, Mullighan C, Loh ML, Norén-Nyström U, Pastorczak A, Shih LY, Zaliova M, Pui CH, Haas OA, Harrison CJ, Moorman AV, Manabe A: Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: A retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia. 2021. PMID: 33692463.

Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu HC, Locatelli F, Loh ML, Manabe A, Mann G, Pieters R, Pui CH, Rives S, Schmiegelow K, Silverman LB, Stary J, Vora A, Brown P. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood. 2022. PMID: 34192312.

Attarbaschi A, Möricke A, Harrison CJ, Mann G, Baruchel A, De Moerloose B, Conter V, Devidas M, Elitzur S, Escherich G, Hunger SP, Horibe K, Manabe A, Loh ML, Pieters R, Schmiegelow K, Silverman LB, Stary J, Vora A, Pui CH, Schrappe M, Zimmermann M. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study. J Clin Oncol. 2022. PMID: 36256911.

Ohki K, Butler E, Kiyokawa N, Hirabayashi S, Bergmann A, Moericke A, Boer J, Cave H, Cazzaniga G, Yeoh A, Sanada M, Imamura T, Inaba H, Mullighan C, Loh M, Norén-Nyström U, Shih LY, Zaliova M, Pui CH, Haas O, Harrison C, Moorman A, Manabe A: Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: A retrospective study by the Ponte di Legno Childhood ALL Working Group. Leukemia. 2023. PMID: 36309560.

Committee members

Andishe Attarbaschi; Edit Bardi; Andre Baruchel; Andrea Biondi; Luis Castillo; Valentino Conter; Ximo Duarte; Sarah Elitzur; Gaby Escherich; Marisa Felice; Mats Heyman; Csongor Kiss; Alexandra Kolenova; Gabor Kovacs; Franco Locatelli; Atsushi Manabe; Veerle Mondelaers; Anja Möricke; J John Moppett; Rob Pieters; Susana Rives; Carmelo Rizzari; Sujith Samarasinghe; Martin Schrappe; Owen Smith; Jan Stary; Anne Uyttebroeck; Maria Grazia Valsecchi; Inge van der Sluis; Tomasz Szczepanski; Luciana Vinti; Ajay Vora; Martin Zimmermann; Myriam Campbell; Toby Trahair; Gunnar Cario; Marion Strullu; Arndt Borkhardt; Shai Izraeli; Marin Stanulla; Anthony Moorman; Chris Halsey; Olli Lohi; Kjeld Schmiegelow; and many other regular and irregular participants.